Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Resource Center

ONLINE EXCLUSIVES
CPC+CBEx Abstracts
10/15/2025
For this year's Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), authors contributed research that presented real-world evidence, conceptual models, and proposals designed to inform the development and refinement of...
For this year's Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), authors contributed research that presented real-world evidence, conceptual models, and proposals designed to inform the development and refinement of...
For this year's Clinical...
10/15/2025
Journal of Clinical Pathways
Adam Kittai
Interview
Redefining Outcomes in Richter Transformation
06/17/2025
Adam Kittai, MD
A guest expert discusses how the shift to targeted therapies is reshaping survival outcomes and research priorities for patients with Richter transformation in chronic lymphocytic leukemia.
A guest expert discusses how the shift to targeted therapies is reshaping survival outcomes and research priorities for patients with Richter transformation in chronic lymphocytic leukemia.
A guest expert discusses how the...
06/17/2025
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
From Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shield...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024
Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023
Grace Taylor, MS, MA
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023
Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023
Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways

Expert Insights

Adam Kittai
Interview
Redefining Outcomes in Richter Transformation
06/17/2025
Adam Kittai, MD
A guest expert discusses how the shift to targeted therapies is reshaping survival outcomes and research priorities for patients with Richter transformation in chronic lymphocytic leukemia.
A guest expert discusses how the shift to targeted therapies is reshaping survival outcomes and research priorities for patients with Richter transformation in chronic lymphocytic leukemia.
A guest expert discusses how the...
06/17/2025
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shield...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
Adam Kittai, MD
Videos
A Real-World Analysis of Factors Leading to Racial Disparities in the Overall Survival of Patients with CLL
06/22/2023
Adam Kittai, MD
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State...
06/22/2023
Journal of Clinical Pathways
Winston Wong
Editor Insights
A Look Back at Clinical Pathways in 2022
02/21/2023
Winston Wong, PharmD
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal...
02/21/2023
Journal of Clinical Pathways
Justin Taylor, MD
Videos
Recent Advances in Chronic Lymphocytic Leukemia Treatment
12/06/2022
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a...
12/06/2022
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Progression-Free Survival Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
08/19/2022
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a...
08/19/2022
Journal of Clinical Pathways
Adam Kittai, MD
Videos
Examining Racial and Socioeconomic Disparities Among Patients With Chronic Lymphocytic Leukemia
06/14/2022
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his...
06/14/2022
Journal of Clinical Pathways
Videos
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
Joanna M. Rhodes, MD, MSCE
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways

Newsfeed

News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024
Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023
Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023
Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
News
Study Analyzes Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
05/11/2023
Grace Taylor, MS, MA
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS,...
05/11/2023
Journal of Clinical Pathways
News
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
04/24/2023
Gina Tomaine
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food...
04/24/2023
Journal of Clinical Pathways
News
The Ongoing Impact of COVID-19 on Caregivers of Patients With Chronic Lymphocytic Leukemia
03/15/2023
Grace Taylor, MS, MA
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the...
03/15/2023
Journal of Clinical Pathways
News
Elevated Risk of Atrial Fibrillation or Stroke in Patients With CLL Receiving Ibrutinib Treatment Has Minimal Impact on TTNT and TTD
02/23/2023
Grace Taylor, MS, MA
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the...
02/23/2023
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways
News
Real-World Data Support Earlier T-DXd Use in HR+/HER2-Low Metastatic Breast Cancer
03/04/2026
Grace Taylor, MS, MA
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab...
03/04/2026
Journal of Clinical Pathways
News
Neighborhood Socioeconomic Status Tied to Survival in US Early-Onset Metastatic Colorectal Cancer
02/19/2026
Hannah Musick
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort...
02/19/2026
Journal of Clinical Pathways
News
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in Metastatic TNBC
02/13/2026
Grace Taylor, MS, MA
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3...
02/13/2026
Journal of Clinical Pathways
News
Mobile App Self-Acupressure Reduces Ovarian Cancer Fatigue, Study Finds
02/13/2026
Grace Taylor, MS, MA
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided...
02/13/2026
Journal of Clinical Pathways
News
Interlocking Poverty, Stigma, and Information Gaps Drive Hospice Exclusion for Low-Income Cancer Patients
02/13/2026
Lisa Kuhns, PhD, MD
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among...
02/13/2026
Journal of Clinical Pathways
News
Patient Navigation Improves Colorectal Cancer Screening in Washington, DC Safety Net
02/11/2026
Hannah Musick
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC...
02/11/2026
Journal of Clinical Pathways
News
Tumor-Informed ctDNA Surveillance for HCC and CCA After Liver Transplant Shows High Specificity
02/09/2026
Grace Taylor, MS, MA
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed...
02/09/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL
04/18/2022
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL...
04/18/2022
Journal of Clinical Pathways
Quiz
Quiz: The Impact of Atrial Fibrillation on CLL
03/24/2022
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL...
03/24/2022
Journal of Clinical Pathways
Quiz
Quiz: Risk of Infusion Reactions in Patients With CLL Receiving Obinutuzumab
02/22/2022
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using...
02/22/2022
Journal of Clinical Pathways
Quiz
Quiz: Ibrutinib Safety for Relapsed/Refractory CLL
01/13/2022
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent...
01/13/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Venetoclax Plus Obinutuzumab for CLL
11/22/2021
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration...
11/22/2021
Journal of Clinical Pathways
Quiz
Quiz: Treatment Discontinuation Among Patients With CLL
10/19/2021
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common...
10/19/2021
Journal of Clinical Pathways
Quiz
Quiz: Cardiovascular Risks for Patients With CLL Receiving Ibrutinib
10/08/2021
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is...
10/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Bendamustine Costs for Patients With CLL and NHL
09/10/2021
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume,...
09/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Cost for CLL and NHL
07/23/2021
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous...
07/23/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use